Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Comprehensive genomic sequencing detects important genetic differences between right-sided and left-sided colorectal cancer.

Shimada Y, Kameyama H, Nagahashi M, Ichikawa H, Muneoka Y, Yagi R, Tajima Y, Okamura T, Nakano M, Sakata J, Kobayashi T, Nogami H, Maruyama S, Takii Y, Hayashida T, Takaishi H, Kitagawa Y, Oki E, Konishi T, Ishida F, Kudo SE, Ring JE, Protopopov A, Lyle S, Ling Y, Okuda S, Ishikawa T, Akazawa K, Takabe K, Wakai T.

Oncotarget. 2017 Aug 24;8(55):93567-93579. doi: 10.18632/oncotarget.20510. eCollection 2017 Nov 7.

2.

Utility of comprehensive genomic sequencing for detecting HER2-positive colorectal cancer.

Shimada Y, Yagi R, Kameyama H, Nagahashi M, Ichikawa H, Tajima Y, Okamura T, Nakano M, Nakano M, Sato Y, Matsuzawa T, Sakata J, Kobayashi T, Nogami H, Maruyama S, Takii Y, Kawasaki T, Homma KI, Izutsu H, Kodama K, Ring JE, Protopopov A, Lyle S, Okuda S, Akazawa K, Wakai T.

Hum Pathol. 2017 Aug;66:1-9. doi: 10.1016/j.humpath.2017.02.004. Epub 2017 Feb 22.

3.

Genomic landscape of colorectal cancer in Japan: clinical implications of comprehensive genomic sequencing for precision medicine.

Nagahashi M, Wakai T, Shimada Y, Ichikawa H, Kameyama H, Kobayashi T, Sakata J, Yagi R, Sato N, Kitagawa Y, Uetake H, Yoshida K, Oki E, Kudo SE, Izutsu H, Kodama K, Nakada M, Tse J, Russell M, Heyer J, Powers W, Sun R, Ring JE, Takabe K, Protopopov A, Ling Y, Okuda S, Lyle S.

Genome Med. 2016 Dec 22;8(1):136. doi: 10.1186/s13073-016-0387-8.

4.

Nuclear FAK controls chemokine transcription, Tregs, and evasion of anti-tumor immunity.

Serrels A, Lund T, Serrels B, Byron A, McPherson RC, von Kriegsheim A, Gómez-Cuadrado L, Canel M, Muir M, Ring JE, Maniati E, Sims AH, Pachter JA, Brunton VG, Gilbert N, Anderton SM, Nibbs RJ, Frame MC.

Cell. 2015 Sep 24;163(1):160-73. doi: 10.1016/j.cell.2015.09.001.

5.

Targeting PYK2 mediates microenvironment-specific cell death in multiple myeloma.

Meads MB, Fang B, Mathews L, Gemmer J, Nong L, Rosado-Lopez I, Nguyen T, Ring JE, Matsui W, MacLeod AR, Pachter JA, Hazlehurst LA, Koomen JM, Shain KH.

Oncogene. 2016 May;35(21):2723-34. doi: 10.1038/onc.2015.334. Epub 2015 Sep 21.

6.

PI3K/mTOR dual inhibitor VS-5584 preferentially targets cancer stem cells.

Kolev VN, Wright QG, Vidal CM, Ring JE, Shapiro IM, Ricono J, Weaver DT, Padval MV, Pachter JA, Xu Q.

Cancer Res. 2015 Jan 15;75(2):446-55. doi: 10.1158/0008-5472.CAN-14-1223. Epub 2014 Nov 28.

7.

Pyk2 promotes tumor progression in multiple myeloma.

Zhang Y, Moschetta M, Huynh D, Tai YT, Zhang Y, Zhang W, Mishima Y, Ring JE, Tam WF, Xu Q, Maiso P, Reagan M, Sahin I, Sacco A, Manier S, Aljawai Y, Glavey S, Munshi NC, Anderson KC, Pachter J, Roccaro AM, Ghobrial IM.

Blood. 2014 Oct 23;124(17):2675-86. doi: 10.1182/blood-2014-03-563981. Epub 2014 Sep 12.

8.

Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship.

Shapiro IM, Kolev VN, Vidal CM, Kadariya Y, Ring JE, Wright Q, Weaver DT, Menges C, Padval M, McClatchey AI, Xu Q, Testa JR, Pachter JA.

Sci Transl Med. 2014 May 21;6(237):237ra68. doi: 10.1126/scitranslmed.3008639.

9.

The selectivity of austocystin D arises from cell-line-specific drug activation by cytochrome P450 enzymes.

Marks KM, Park ES, Arefolov A, Russo K, Ishihara K, Ring JE, Clardy J, Clarke AS, Pelish HE.

J Nat Prod. 2011 Apr 25;74(4):567-73. doi: 10.1021/np100429s. Epub 2011 Feb 24.

10.

The alpha6beta4 integrin maintains the survival of human breast carcinoma cells in vivo.

Lipscomb EA, Simpson KJ, Lyle SR, Ring JE, Dugan AS, Mercurio AM.

Cancer Res. 2005 Dec 1;65(23):10970-6.

Supplemental Content

Support Center